Novartis Foundation launches new leprosy strategy at symposium on disease elimination

NovartisToday's symposium of the Novartis Foundation for Sustainable Development (NFSD) convenes experts to discuss "What does it take to eliminate a disease?" Drawing lessons from previous successful disease control programs, the symposium speakers discuss innovative approaches and advocate for new coordination strategies in disease elimination efforts.

The Novartis Foundation for Sustainable Development today also announces the launch of a new leprosy strategy based on the consensus reached by a group of leading experts earlier this year. The new strategy focuses on interrupting leprosy transmission through early diagnosis and treatment, contact tracing of former patients, diagnostic tools and strict surveillance and response.

"As part of our pledge to fight neglected diseases in the developing world, Novartis and the Novartis Foundation for Sustainable Development are committed to going the last mile to help make leprosy history," says Joseph Jimenez, CEO of Novartis, in an address to the symposium today. "This devastating disease is curable and I am proud that our donation of multidrug therapy (MDT) has helped treat over 5 million patients since 2000."

Thanks to the availability of MDT, according to the World Health Organization (WHO), more than 15 million patients have been cured of leprosy since 1981, shrinking the worldwide prevalence by approximately 95%. Over the past eight years, however, the number of newly diagnosed leprosy patients has plateaued at around 230,000 cases per year. As experience with other disease control programs has shown, going the last mile is often the hardest. Waning knowledge means that as prevalence decreases, so do political will and funding.

"The key to eradicating smallpox was a comprehensive approach including the availability of an effective, heat stable vaccine, epidemiological surveillance, thorough research, involvement of local communities as well as strong management and commitment by the respective governments," says Professor Donald Henderson, former Head of the WHO's Smallpox Eradication Campaign. "Current elimination programs can also draw on these lessons learned."

Moving forward, the Novartis Foundation plans to take steps to demonstrate the feasibility and efficacy of this strategy in several sites in Asia, Africa and Latin America. "Zero transmission of leprosy is achievable, but we need to be better equipped and use innovative approaches if we are to find and treat the last patients," says Ann Aerts, Head of the Novartis Foundation. "In collaboration with our partners, we want to play a key role in curbing the incidence of leprosy."

About the Novartis Foundation for Sustainable Development
The Novartis Foundation for Sustainable Development is a nonprofit organization whose activities form part of the Corporate Responsibility portfolio of Novartis AG. For over 30 years, the Novartis Foundation has served as a competence center for corporate responsibility and international health, focused on underserved communities. NFSD aims to improve access to healthcare, strengthen human resources in health and empower vulnerable groups. The foundation also fosters dialogue and networking, acting as a bridge between the private sector, international organizations, governments and NGOs.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time equivalent associates and operate in more than 140 countries around the world.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]